These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 33986543)

  • 1. Tocilizumab for the treatment of severe COVID-19.
    O'Leary K
    Nat Med; 2021 May; ():. PubMed ID: 33986543
    [No Abstract]   [Full Text] [Related]  

  • 2. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab: From Rheumatic Diseases to COVID-19.
    Raiteri A; Piscaglia F; Granito A; Tovoli F
    Curr Pharm Des; 2021; 27(13):1597-1607. PubMed ID: 33719967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab.
    De Biasi S; Mattioli M; Meschiari M; Lo Tartaro D; Paolini A; Borella R; Neroni A; Fidanza L; Busani S; Girardis M; Coppi F; Mattioli AV; Guaraldi G; Mussini C; Cossarizza A; Gibellini L
    Front Immunol; 2023; 14():1123807. PubMed ID: 37215114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.
    Sandhu G; Piraino ST; Piticaru J
    Am J Ther; 2022 May-Jun 01; 29(3):e275-e278. PubMed ID: 35249968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Ventilator-free days" composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis.
    Mady AF; Abdulrahman B; Mumtaz SA; Al-Odat MA; Kuhail A; Altoraifi R; Alshae R; Alharthy AM; Aletreby WT
    Heart Lung; 2022; 56():118-124. PubMed ID: 35839546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence.
    Visvabharathy L; Orban ZS; Koralnik IJ
    Front Med (Lausanne); 2022; 9():1003103. PubMed ID: 36213654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.
    Bacca E; Digaetano M; Meschiari M; Franceschini E; Menozzi M; Cuomo G; Mussini C
    Biochem Biophys Res Commun; 2021 Jan; 538():151-155. PubMed ID: 33303188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of tocilizumab on mortality, readmissions, persistent symptoms and lung function in SARS-CoV-2 patients 1 year after hospital discharge: A matched cohort study.
    Cardona-Pascual I; Pallero M; Berlana D; Villar A; Montoro-Ronsano JB; Berastegui C
    Respir Med Res; 2023 Nov; 84():101064. PubMed ID: 38029650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tocilizumab in COVID-19: A review of the current evidence.
    Alam W; Bizri AR
    Sci Prog; 2021; 104(3):368504211030372. PubMed ID: 34236264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.
    Eşkazan AE; Balkan İİ; Demirbaş KC; Ar MC; Karaali R; Sekibağ Y; Mulamahmutoğlu S; Yartaş Dumanlı G; Çakmak F; Özgür Yurttaş N; Kurt F; Aladağ Kurt S; Kuşkucu M; Ürkmez S; Börekçi Ş; Saribal D; Mete B; Bavunoğlu I; Dikmen Y; Aygün G; Midilli K; Tabak F
    J Infect Chemother; 2021 Sep; 27(9):1329-1335. PubMed ID: 34120824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies.
    Sarfraz A; Sarfraz Z; Sarfraz M; Aftab H; Pervaiz Z
    Turk J Med Sci; 2021 Jun; 51(3):890-897. PubMed ID: 33244947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.
    Martínez-Guerra BA; de-León-Cividanes NA; Tamez-Torres KM; Román-Montes CM; Rajme-López S; Ortiz-Brizuela E; Aguilar-Salinas CA; Sierra-Madero J; Sifuentes-Osornio J; Ponce-de-León A; González-Lara MF
    Rev Invest Clin; 2022 Jan; 74(1):40-50. PubMed ID: 34618802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
    Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
    Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection.
    Bouchlarhem A; Es-Saad O; Haddar L; Lamzouri O; Elaidouni G; Mimouni H; Bkiyar H; Housni B
    J Int Med Res; 2022 Mar; 50(3):3000605221082875. PubMed ID: 35301903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
    Masuccio FG; Lo Re M; Bertolotto A; Capobianco M; Solaro C
    Mult Scler Relat Disord; 2020 Nov; 46():102592. PubMed ID: 33296987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
    Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
    Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.